Certara (NASDAQ:CERT) Coverage Initiated at Morgan Stanley

Morgan Stanley assumed coverage on shares of Certara (NASDAQ:CERT - Free Report) in a research note published on Thursday morning, MarketBeat.com reports. The brokerage issued an equal weight rating and a $16.00 target price on the stock.

Other equities analysts have also recently issued research reports about the stock. KeyCorp boosted their price objective on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Robert W. Baird boosted their price target on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. Finally, JMP Securities restated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $15.71.

Certara Trading Down 1.4%

Shares of NASDAQ CERT traded down $0.16 during midday trading on Thursday, reaching $11.33. The company had a trading volume of 1,281,456 shares, compared to its average volume of 1,454,970. The firm's fifty day moving average price is $11.71 and its 200-day moving average price is $11.85. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. Certara has a one year low of $8.64 and a one year high of $16.93. The stock has a market cap of $1.84 billion, a PE ratio of -566.50 and a beta of 1.43.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The firm had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. During the same quarter last year, the business earned $0.10 earnings per share. The business's revenue was up 9.7% on a year-over-year basis. On average, equities research analysts anticipate that Certara will post 0.28 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CERT. Versant Capital Management Inc raised its stake in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after buying an additional 1,866 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Certara during the first quarter valued at about $31,000. Wells Fargo & Company MN lifted its holdings in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after purchasing an additional 1,047 shares in the last quarter. AlphaQuest LLC bought a new position in shares of Certara during the first quarter worth $39,000. Finally, Johnson Financial Group Inc. bought a new stake in shares of Certara in the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.